Summary
The product Clalis 20mg, with an unknown manufacturer and batch number, underwent independent testing to verify its authenticity and potency. The sample was submitted by the manufacturer acepharmaadmin@protonmail.com and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Tadalafil, with a concentration of 18.23 mg, which is 8.85% below the labeled claim of 20 mg.
The testing process began on 15 DEC ’23, with the sample received on 29 DEC ’23, and analysis completed on 03 JAN 2024. While the results indicate a slight underdosing, scrutiny of manufacturer-submitted samples is essential to ensure reliability. Manufacturer may select specific batches for testing, raising questions about product consistency across the broader market. Independent third-party testing remains critical to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Unknown
- Product Name: Clalis 20mg
- Active Ingredient: Tadalafil
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #37036
- Testing Ordered: 15 DEC ’23
- Sample Received: 29 DEC ’23
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: ACE Pharmaceuticals (Manufacturer)
- Analysis Paid For By: ACE Pharmaceuticals (Manufacturer)
Testing Results
- Specification: 20 mg (as stated on the label)
- Measured Concentration: 18.23 mg
- Accuracy: 91.15% (8.85% below the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/37036_HNS78RPUTW7F
Evaluation of Manufacturer-Submitted Testing
This analysis highlights the underdosing of the tested product but warrants careful evaluation due to its submission by the manufacturer acepharmaadmin@protonmail.com. Manufacturer often select specific batches for testing, which may not fully represent the consistency of products available to consumers. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple batches.
Conclusion
The analysis confirms that Clalis 20mg is slightly underdosed, with a measured concentration of 18.23 mg. This result reflects potential quality control issues for this batch and underscores the importance of additional testing to ensure consistent dosing across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding pharmaceutical products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
